Yazar "Ertaş, Yavuz Nuri" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Micelle-engineered nanoplatforms for precision oncology
    (Elsevier science, 2024) Gao, Wei; Bigham, Ashkan; Ghomi, Matineh; Zarrabi, Ali; Rabiee, Navid; Saeb, Mohammad Reza; Ertaş, Yavuz Nuri; Goel, Arul; Sharifi, Esmaeel; Ashrafizadeh, Milad; Sethi, Gautam; Tambuwala, Murtaza M.; Wang, Yuzhuo; Ghaffarlou, Mohammadreza; Jiao, Taiwei
    The alliance between nanomaterials and cancer therapy has revolutionized the treatment of tumor patients. After cardiovascular diseases, cancer is the leading cause of death, so interdisciplinary approaches should be used for the treatment of this malignant disease. Both treatment and early diagnosis of cancer are challenging. The micelles belong to lipid-based nanostructures, and they have a hydrophobic core with hydrophilic head regions. The current review article focuses on the application of micelles in cancer suppression. The micelles can provide a platform for co-delivery of non-coding RNAs and RNAi in cancer gene therapy. Both synthetic and natural
  • Küçük Resim Yok
    Öğe
    Nanoliposomes as nonviral vectors in cancer gene therapy
    (John Wiley and Sons Inc, 2024) Yıldız, Safiye Nur; Entezari, Maliheh; Paskeh, Mahshid Deldar Abad; Mirzaei, Sepideh; Kalbasi, Alireza; Zabolian, Amirhossein; Hashemi, Farid; Hushmandi, Kiavash; Hashemi, Mehrdad; Raei, Mehdi; Goharrizi, Mohammad Ali Sheikh Beig; Aref, Amir Reza; Zarrabi, Ali; Ren, Jun; Orive, Gorka; Rabiee, Navid; Ertaş, Yavuz Nuri
    Nonviral vectors, such as liposomes, offer potential for targeted gene delivery in cancer therapy. Liposomes, composed of phospholipid vesicles, have demonstrated efficacy as nanocarriers for genetic tools, addressing the limitations of off-targeting and degradation commonly associated with traditional gene therapy approaches. Due to their biocompatibility, stability, and tunable physicochemical properties, they offer potential in overcoming the challenges associated with gene therapy, such as low transfection efficiency and poor stability in biological fluids. Despite these advancements, there remains a gap in understanding the optimal utilization of nanoliposomes for enhanced gene delivery in cancer treatment. This review delves into the present state of nanoliposomes as carriers for genetic tools in cancer therapy, sheds light on their potential to safeguard genetic payloads and facilitate cell internalization alongside the evolution of smart nanocarriers for targeted delivery. The challenges linked to their biocompatibility and the factors that restrict their effectiveness in gene delivery are also discussed along with exploring the potential of nanoliposomes in cancer gene therapy strategies by analyzing recent advancements and offering future directions. © 2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.